Advertisement

International Ophthalmology

, Volume 38, Issue 6, pp 2397–2402 | Cite as

Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration

  • Hasan AltinkaynakEmail author
  • Meltem Ece Kars
  • Piraye Zeynep Kurkcuoglu
  • Nagihan Ugurlu
Original Paper
  • 152 Downloads

Abstract

Purpose

The aim of this study was to evaluate the effect of intravitreal injection of aflibercept (IVA) on blood coagulation tests in neovascular age-related macular degeneration (AMD) patients.

Methods

Thirty-four patients with neovascular AMD (study group) and 32 healthy individuals (control group) were enrolled. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were measured at different times in patients with neovascular AMD.

Results

The levels of PT and aPTT after IVA were decreased at 1 month after the first injection and 1 month after the second injection compared to the baseline measurement in the study group.

Conclusions

IVA may cause a decrease in the levels of PT and aPTT at 1 month after the first injection and 1 month after the second injection although these results are not statistically significant in our study.

Keywords

Activated partial thromboplastin time Age-related macular degeneration Aflibercept Arterial thrombotic events Prothrombin time 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no financial or proprietary interests.

Ethical approval

The study protocol followed the principles in the declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Klein R, Wang Q, Klein BE et al (1995) The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 36:182–191PubMedGoogle Scholar
  2. 2.
    Munoz B, West SK, Rubin GS et al (2000) Causes of blindness and visual impairment in a population of older Americans: the salisbury eye evaluation study. Arch Ophthalmol 118:819–825CrossRefGoogle Scholar
  3. 3.
    Attebo K, Mitchell P, Smith W (1996) Visual acuity and the causes of visual loss in Australia: the blue mountains eye study. Ophthalmology 103:357–364CrossRefGoogle Scholar
  4. 4.
    Wroblewski JJ, Wells JA, Adamis AP et al (2009) Central retinal vein occlusion study group. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127:374–380CrossRefGoogle Scholar
  5. 5.
    Ehlers JP, Decroos FC, Fekrat S (2001) Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina 31:1856–1862CrossRefGoogle Scholar
  6. 6.
    Campochiaro PA, Heier JS, Feiner L et al (2010) BRAVO investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112CrossRefGoogle Scholar
  7. 7.
    Campochiaro PA, Clark WL, Boyer DS et al (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122:538–544CrossRefGoogle Scholar
  8. 8.
    Evoy KE, Abel SR (2013) Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion. Ann Pharmacother 47:819–827CrossRefGoogle Scholar
  9. 9.
    Sang DN, Damore PA (2008) Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia 51:1570–1573CrossRefGoogle Scholar
  10. 10.
    Von Hanno T, Kinge B, Fossen K (2010) Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 88:263–266CrossRefGoogle Scholar
  11. 11.
    Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 87:77–88CrossRefGoogle Scholar
  12. 12.
    Costagliola C, Agnifili L, Arcidiacono B et al (2012) Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 12:1299–1313CrossRefGoogle Scholar
  13. 13.
    Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–1239CrossRefGoogle Scholar
  14. 14.
    Yoshida I, Shiba T, Taniguchi H et al (2014) Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252:1483–1489CrossRefGoogle Scholar
  15. 15.
    Tripodi A, Mannucci PM (2006) Activated partial thromboplastin time (APTT). New indications for an old test? J Thromb Haemost 4(4):750–751CrossRefGoogle Scholar
  16. 16.
    Favaloro EJ, Lippi G, Adcock DM (2008) Preanalytical and postanalytical variables in haemostasis: the leading causes of diagnostic error? Semin Thromb Hemost 34(7):612–634CrossRefGoogle Scholar
  17. 17.
    Lippi G, Favaloro EJ (2008) Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 34(7):604–611CrossRefGoogle Scholar
  18. 18.
    Tripodi A, Chantarangkul V, Martinelli I et al (2004) A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 104(12):3631–3634CrossRefGoogle Scholar
  19. 19.
    Senthil M, Chaudhary P, Smith DD et al (2014) A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients. Thromb Res 134(1):165–168CrossRefGoogle Scholar
  20. 20.
    Korte W, Clarke S, Lefkowiz JB (2000) Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 113(1):123–127CrossRefGoogle Scholar
  21. 21.
    Legnani C, Mattarozzi S, Cini M et al (2006) Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol 134(2):227–232CrossRefGoogle Scholar
  22. 22.
    Qian J, Jiang YR (2011) Decreased prothrombin time after intravitreal bevacizumab in the early period in patients with proliferative diabetic retinopathy. Acta Ophthalmol 89:332–335CrossRefGoogle Scholar
  23. 23.
    Yi Z, Chen C, Su Y et al (2015) Changes in clotting time, plasma fibrinogen levels, and blood viscosity after administration of ranibizumab for treatment of choroidal neovascularization. Curr Eye Res 40(11):1166–1171CrossRefGoogle Scholar
  24. 24.
    Molenaar PJ, Leyte A (2011) Pre-acquisition system assessment of the Sysmex Coagulation System CS-2100i and comparison with end-user verification; a model fort he regional introduction of new analysers and methods. Clin Chem Lab Med 49(9):1479–1489CrossRefGoogle Scholar
  25. 25.
    Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548CrossRefGoogle Scholar
  26. 26.
    Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193–201CrossRefGoogle Scholar
  27. 27.
    Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611CrossRefGoogle Scholar
  28. 28.
    Zakarija A, Soff G (2005) Update on angiogenesis inhibitors. Curr Opin Oncol 17:578–583CrossRefGoogle Scholar
  29. 29.
    Ng EWM, Adamis AP (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40:353–368Google Scholar
  30. 30.
    Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:1358–1366CrossRefGoogle Scholar
  31. 31.
    Schmid MK, Bachmann LM, Fas L et al (2015) Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol 99:141–146CrossRefGoogle Scholar
  32. 32.
    Ueta T, Noda Y, Toyama T et al (2014) Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. Ophthalmology 121:2193–2203CrossRefGoogle Scholar
  33. 33.
    Thompson SG, Kienast J, Pyke SD et al (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 332:635–641CrossRefGoogle Scholar
  34. 34.
    Tan JS, Wang JJ, Liew G et al (2008) Age related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 92:509–512CrossRefGoogle Scholar
  35. 35.
    Sun C, Klein R, Wong TY (2009) Age-related macular degeneration and risk of coronary heart disease and stroke: the cardiovascular health study. Ophthalmology 116:1913–1919CrossRefGoogle Scholar
  36. 36.
    Hu CC, Ho JD, Lin HC (2010) Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke 41:613–617CrossRefGoogle Scholar
  37. 37.
    Ozkan B, Karabas LV, Altıntas O et al (1995) Plasma antiphospholipid antibody levels in age-related macular degeneration. Can J Ophthalmol 47:264–268CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Hasan Altinkaynak
    • 1
    Email author
  • Meltem Ece Kars
    • 2
  • Piraye Zeynep Kurkcuoglu
    • 3
  • Nagihan Ugurlu
    • 2
  1. 1.Department of OphthalmologyAnkara Atatürk Education and Research HospitalAnkaraTurkey
  2. 2.Department of OphthalmologyYıldırım Beyazıt University, Ankara Atatürk Education and Research HospitalAnkaraTurkey
  3. 3.Department of OphthalmologyWorld Eye HospitalAnkaraTurkey

Personalised recommendations